06/23/22 8:00 AMNasdaq : KTTA, KTTAW conferenceslow floatPasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and BeyondPasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that itsRHEA-AIneutral
06/22/22 8:00 AMNasdaq : KTTA, KTTAW acquisitionlow floatPasithea Therapeutics Acquires Alpha-5 Integrin, LLC- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases - - Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth - - Closing consideration of 3.26 million shares of PasitheaRHEA-AIpositive
04/14/22 4:15 PMNasdaq : KTTA, KTTAW conferenceslow floatPasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced its ChiefRHEA-AIneutral
03/30/22 4:15 PMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022MIAMI BEACH,RHEA-AIvery positive
03/08/22 8:00 AMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Announces Collaboration with The Glimpse GroupPasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” orRHEA-AIpositive
02/24/22 8:00 AMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022MIAMI BEACH, Fla., Feb.RHEA-AIvery positive
02/09/22 8:00 AMNasdaq : KTTA, KTTAW managementlow floatPasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel WeinbergerPasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research andRHEA-AIneutral
02/03/22 8:00 AMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple SclerosisPasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research andRHEA-AIneutral
01/26/22 8:00 AMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine TreatmentsPasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novelRHEA-AIneutral
12/21/21 8:00 AMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United KingdomPasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatricRHEA-AIneutral
